Follow us on Twitter
twitter icon@FreshPatents


Cancer patents

      

This page is updated frequently with new Cancer-related patent applications.

SALE: 200+ Cancer-related patent PDFs



Surrogate functional biomarker for solid tumor cancer
The present invention relates to diagnostic methods that are relevant to various solid tumor cancers that are not amenable to traditional bih3 profiling diagnostic methods. In some embodiments, the methods described herein are useful in the evaluation of a patient, for example, for evaluating diagnosis, prognosis, and response to treatment.
Eutropics Pharmaceuticals, Inc.


Protein biomarker panels for detecting colorectal cancer and advanced adenoma
Disclosed herein are panels related to the diagnosis or recognition of advanced adenoma and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient.
Applied Proteomics, Inc.


Method for identifying or detecting genomic rearrangements in a biological sample
A method for detection, visualization and/or comparison of polynucleotide sequences of interest using specially designed sets of long and short probes that enhance resolution and simplify visualization and detection. Probe compositions useful for practicing this method and procedures for identifying useful probes and probe combinations.
Genomic Vision


Method for determining prognosis of breast cancer patient by using gene expression data
A method for determining prognosis of a breast cancer patient according to an embodiment includes: collecting information on cancer tissue in a patient group from patient information determined to have breast cancer, collecting gene expression information of each patient group, sorting genes by performing a test for a group having a high expression level and a group having a low expression level based on gene expression of each patient group, clustering genes based on expression patterns of the sorted genes, defining a prognostic score using a gene expression ratio for a gene, and deriving prognosis for breast cancer in a patient group by using the prognostic score.. .
Gwangju Institute Of Science And Technology


Dna methylation markers for metastatic prostate cancer
The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer.
The Johns Hopkins University


Method and kit for use in inhiiting tumor progression, predicting or determining tumor progression state in vgf expressing cancers
The present invention provides a method of inhibiting tumor progression in a subject suffering from vgf expressing cancers. The present invention also provides a method and a kit of predicting or determining tumor progression state in a subject suffering from vgf expressing cancers..
Truebio Llc


Organic compositions to treat epas1 - related diseases
The present disclosure relates to methods of treating epas1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, rheumatoid arthritis, using a therapeutically effective amount of a rnai agent to epas1.. .
Arrowhead Pharmaceuticals, Inc.


Cancer cell enrichment system
The present invention describes a method for the propagation of a subpopulation of cells. The subpopulation of cells can be grown in specific culture conditions to promote growth and enrichment of the subpopulation of cells.
Xcell Biosciences, Inc.


Prostate-specific membrane antigen binding proteins and related compositions and methods
The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (psma) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (bph). In one embodiment, the multi-specific poly-peptide therapeutics bind both psma-expressing cells and the t-cell receptor complex on t cells to induce target-dependent t-cell cytotoxicity, activation and proliferation..
Aptevo Research And Development Llc


Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.. .
Mayo Foundation For Medical Education And Research


Novel compounds as rearranged during transfection (ret) inhibitors

This invention relates to novel compounds which are inhibitors of the rearranged during transfection (ret) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to ret dysfunction or where modulation of ret activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (ibs) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, von hippel-lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased ret kinase activity.. .
Glaxosmithkline Intellectual Property Development Limited

Process for the preparation of androgen receptor antagonists and intermediates thereof

The present invention relates to an improved process for the preparation of carboxamide structured androgen receptor (ar) antagonists such as n—((s)-1-(3-(3-chloro-4-cyanophenyl)-1h-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide (1a) and key intermediates thereof such as 2-chloro-4-(1h-pyrazol-3-yl)benzonitrile (v). Ar antagonists are useful in the treatment of cancer, particularly prostate cancer and other diseases where ar antagonism is desired..
Orion Corporation

Anti-fugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides antifugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Topical drug for treating breast cancer and preparation method thereof

Disclosed is a topical drug for treating breast cancer and preparation method thereof. The topical drug comprises the following ingredients in parts by weight: 5-10 parts of astragalus, 3-5 parts of oldenlandia diffusa, 3-5 parts of dandelion, 5-10 parts of lycoris radiate, 5-8 parts of carapax trionycis, 3-5 parts of pinellia pedatisecta, 2-3 parts of acorus calamus, 3-5 parts of ferula sinkiangensis, 3-5 parts of doubleteeth pubescent angelica root, 4-6 parts of cryptotaenia japonica hassk, 3-5 parts of whitmania pigra whitman, 5-8 parts of wedelia chinensis, 6-8 parts of echinacea purpurea, 4-6 parts of folium eriobotryae, 3-5 parts of sedum sarmentosum, 5-10 parts of angelicae sinensis, 2-5 parts of asparagus, 2-3 parts of scorpio, 5-8 parts of rubia cordifolia l., 2-3 parts of alfalfa extract, 3-5 parts of extract of jew's ear from mulberry trees, 5-7 parts of myrrh, 3-6 parts of nutgrass galingale rhizome and 3-5 parts of pericarpium citri reticulatae viride..

Detargeted adenovirus variants and related methods

The present disclosure describes the generation and the use of ad variants (ad) possessing any combination of mutations in genes that code for the hexon, penton, fiber, and non-structural proteins, where simultaneous modification of hexon and penton are made to avoid the trapping of ad in the liver and to reduce toxicity after intravascular virus administration. Such liver de-targeted ad can be useful tool for selective and specific gene delivery to extra-hepatic tissues and cells, including disseminated metastatic cancer cells..

Engineered oncolytic viruses containing hyper-binding sites to sequester and suppress activity of oncogenic transcription factors as a novel treatment for human cancer

In one or more embodiments, the present invention provides novel artificial, non-naturally-occurring double stranded dna segments (and related methods) capable of acting as decoy binding sites for oncogenic transcription factors and a general method for suppressing aberrant activity of oncogenic transcription factors that promote cancer progression. In various embodiments, the present invention involves the sequestration of targeted oncogenic transcription factors at these artificial, non-naturally occurring engineered transcription factor binding sites, which have been introduced into the cells using oncolytic or other viruses that can be engineered to selectively target cancer cells.
Miami University

Tumor-selective combination therapy

The therapies described herein can be selectively lethal toward a variety of different cancer cell types and cancer conditions in a subject. The combination therapies described herein can be useful for the management, treatment, control, or adjunct treatment of diseases, where the selective legality is beneficial in chemotherapeutic therapy, particularly where the disease is accompanied by elevated levels of nqo1..
The Board Of Trustees Of The University Of Illinois

Lasofoxifene treatment of breast cancer

The disclosure provides methods for treating estrogen receptor positive (er+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the estrogen receptor 1 (esr1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant er+ cancers..
Duke University

Therapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment of cancers

An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of apigenin, cannflavin. A.
Flavocure Biotech Llc

Method for treating bladder cancer

A method for treating bladder cancer including the steps of administering an isothiocyanate functional surfactant to an area affected by bladder cancer, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.. .

Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts risk of prostate cancer progression in a patient, where the model is based on features including one or more (e.g., all) of preoperative psa, dominant gleason grade, gleason score, at least one of a measurement of expression of ar in epithelial and stromal nuclei and a measurement of expression of ki67-positive epithelial nuclei, a morphometric measurement of average edge length in the minimum spanning tree (mst) of epithelial nuclei, and a morphometric measurement of area of non-lumen associated epithelial cells relative to total tumor area.
Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud,dba Champalimaud Fnd.

Method for diagnosing and treating ovarian cancer

Provided are a composition, a kit, and a method of predicting prognosis of ovarian cancer or a risk of recurrence of ovarian cancer. Provided are a composition for treating ovarian cancer or preventing recurrence of ovarian cancer and a method of screening a material for treating ovarian cancer or preventing recurrence of ovarian cancer.
Sungkwang Medical Foundation

Standard cell suspension

The present invention relates to a standard cell suspension for confirming the stainability of a treatment solution that differentially stains circulating tumor cells (ctcs) and leucocytes, containing (a) a cell line having an antigen that is specific for human cancer cells and (b) a cell line having an antigen that is specific for human leukocytes, wherein the (a) and (b) components are each a cell line that is fixed by a cell-fixing reagent.. .
Hitachi Chemical Company, Ltd.

Solid tumor methylation markers and uses thereof

Disclosed herein are methods and kits for identifying a subject as having esophagus cancer, pancreatic cancer, or stomach cancer. Also provided herein are methods and kits for generating the methylation profile of a biomarker associated with esophagus cancer, pancreatic cancer, or stomach cancer..
The Regents Of The University Of California

Biomarker for predicting colon cancer responsiveness to anti-tumor treatment

The present invention provides a biomarker, namely cdx2, and surrogate cdx2 biomarkers, the expression level of which is useful in predicting response of cancer patients to therapy with an egfr inhibitor.. .
The Trustees Of Columbia University In The City Of New York

Compositions and methods for determining endometrial cancer prognosis

The present invention provides methods and compositions for determining prognosis in individual with cancer, in particular endometrial cancer. The present invention also provides methods of developing and using predictive models that are useful for determining prognosis of endometrial cancer and other similar diseases.
Quest Diagnostics Investments Llc

Anti-prlr antibodies and uses thereof

The present invention provides antibodies that bind to prolactin receptor (prlr) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human prlr with high affinity.
Regeneron Pharmaceuticals, Inc.

Antibodies that bind cell surface grp78 and their use for detection of cancer

This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting cell surface grp78 expressed on tumor cells, tumor endothelial cells, and tumor initiating cancer cells. These anti-grp78 antibodies, or antigen-binding fragments thereof, have a high affinity for grp78 and are less immunogenic compared to their unmodified parent antibodies in a given species, e.g., a human, and function to inhibit grp78.

Vaccines against her3 antigens and methods of using the same

The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon her2-mediated signaling..
Duke University

Lung cancer diagnosis marker, antibody and application thereof

A human lung cancer marker n3g4, and use of the same as human lung cancer marker is disclosed. Hybridoma cells which produce anti-n3g4 monoclonal antibodies, and the secreted monoclonal antibody lc128, and use of lc128 for the preparation of a diagnostic agent for lung cancer are also disclosed.

Chemical compounds

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit cdk9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large b cell lymphoma, burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer..
Astrazeneca Ab

5h-pyrido[3,2-b]indole compounds as anticancer agents

The present invention is directed to tricyclic compounds of formula (i), pharmaceutically acceptable compositions comprising compounds of the invention and said compositions for use in methods for the treatment of various disorders in particular cancer.. .
Bristol-mayers Squibb Company

Antibodies to il-6 and use thereof

The present invention is directed to therapeutic methods using il-6 antagonists such as an ab1 antibody or antibody fragment having binding specificity for il-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum c-reactive protein level, reduced serum albumin level, elevated d-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment.
Alderbio Holdings Llc

Mitochondrial antiviral signaling (mavs) protein compositions and methods of using the same

The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to mavs compositions and their use in cancer therapeutics that may be used to treat various cancers alone or in combination with other anti-cancer therapeutic agents..
Duke University

Novel monoclonal antibody inhibitors targeting potassium channel kcnk9

The presently disclosed subject matter relates to antibodies, antibody fragments or derivatives thereof, which specifically bind to and/or interact with at least one epitope of the extracellular domain of the mammalian kcnk9 potassium channel, and to nucleic acid molecules encoding the same, as well as to vectors comprising said nucleic acid molecules. The presently disclosed subject matter provides methods for the preparation of said antibodies, antibody fragments or derivatives thereof, as well as pharmaceutical compositions, diagnostic compositions, and kits comprising the same.
The Johns Hopkins University

Therapeutic cancer vaccine targeted to haah (aspartyl-[asparaginyl]-beta-hydroxylase

The present invention encompasses a cancer vaccine therapy targeting aspartyl-[asparaginyl]-,8-hydroxylase (haah). The present invention contemplate bacteriophage expressing haah peptide fragments and methods for using said bacteriophage in methods of treating cancer..
Panacea Pharmaceuticals, Inc.

Mesalamine for the treatment of cancer

Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation..
Cipla Limited

Small molecule enhancer for dendritic cell cancer vaccines

Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dash serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of t-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian dash serine proteases.
Trustees Of Tufts College

Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer

Disclosed herein are novel biomarkers for detecting resistance and sensitivity to abiraterone acetate-glucocorticoid treatment in a patient having metastatic castration resistant prostate cancer. Also provided are methods of diagnosing and treating abiraterone acetate-glucocorticoid resistant and abiraterone acetate-glucocorticoid sensitive metastatic castration resistant prostate cancer..
Janssen Pharmaceutica Nv

Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment

A method for determining colorectal cancer risk includes obtaining a blood sample of the subject, isolating serum or edta plasma from the blood sample, analyzing the serum or edta plasma to determine plasma levels of very long chain dicarboxylic acid (vlcdca 28:4), comparing the determined plasmas level of vlcdca 28:4 of the subject with a predetermined range of plasma levels of vlcdca 28:4 of diagnosed subjects having colorectal cancer, and determining a colorectal cancer risk exists when the determined plasma level of vlcdca 28:4 is within the predetermined range of plasma levels of vlcdca.. .
Lincoln Memorial University

Substituted n-([1,1'-biphenyl]-3-yl)-[1,1'-biphenyl]-3-carboxamide analogs as inhibitors for beta-catenin/b-cell lymphoma 9 interactions

In one aspect, the invention relates to substituted n-([1,1′-biphenyl]-3-yl)-[1,1′-biphenyl]-3-carboxamide analogues, derivatives thereof, and related compound; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders, e.g., various tumors and cancers, associated with β-catenin/bcl9 protein-protein interaction dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
University Of Utah Research Foundation

Method of identifying proteins in human serum indicative of pathologies of human lung tissues

A method of identifying proteins present in human serum which are differentially expressed between normal individuals and patients known to have non-small cell lung cancers and asthma, as diagnosed by a physician. Human serum specimens from each population are digested with trypsin or any other suitable endoproteinase and analyzed using a liquid chromatography electrospray ionization mass spectrometer.
Cancer, Prevention, And Cure, Ltd.

Elevated psma identifies lethal prostate cancers

Prostate cancer (pc) is an entity that encompasses different types of tumors, including adenocarcinomas and non-adenocarcinomas. Adenocarcinomas and non-adenocarcinomas respond to, and therefore should be treated, with different treatments.
Cornell University

High resolution assays for prostate cancer

Also provided in an embodiment a high resolution method of detecting prostate cancer comprising utilizing a solid phase immunoassay to determine if a patient serum shows a mic-1 value and a psa value in zone a (defined below) or, if utilized, zone b. In an embodiment, the method comprises conducting a sandwich assay in an assay device that, if the determined value is in zone a and/or zone b, automatically generates a report stating that a high risk of prostate cancer exists..

Medical analysis device and cell analysis method

The present invention provides a medical analysis device and a cell analysis method with which it is possible to count the number of cancer cells, culture the cancer cells, and determine the effect of drugs on the cancer cells. The present invention relates to a medical analysis device intended to capture cancer cells, the medical analysis device having multiple wells..
Yamagata University

Method for capturing cancer cells

The present invention provides a method for capturing cancer cells which can capture many types of cancer cells, including cancer cells not expressing epcam. The present invention relates to a method for capturing cancer cells present in biological fluid, the method including reducing the protein level of sampled biological fluid, followed by capturing cancer cells using a hydrophilic polymer layer..
Yamagata University

Mirna fingerprint in the diagnosis of lung cancer

The present invention provides novel methods for diagnosing diseases based on the determination of specific mirnas that have altered expression levels in disease states compared to healthy controls.. .
Comprehensive Biomarker Center Gmbh

Medical analysis device and cell analysis method

The present invention provides a medical analysis device and a cell analysis method, which can capture many types of cancer cells, including cancer cells not expressing epcam. The present invention relates to a medical analysis device having a well portion, the well portion having a hydrophilic polymer layer formed at least partly on the inner surface thereof, the hydrophilic polymer layer having fibronectin adsorbed thereto..
Yamagata University

Immunogenic peptides of the cyclin b1 tumor antigen

The present invention relates to peptides comprising at least one cd4+ t epitope, which is immunodominant in vitro, of the cyclin b1 tumor antigen, said peptides being capable of stimulating a specific human cd4+ t lymphocyte response in subjects who have varied hla ii molecules, and to the use of these peptides as a cancer vaccine and as a reagent for the diagnosis of cancer or the immunomonitoring of the cellular response against cyclin b1 during cancer or during an anticancer treatment.. .
Commissariat A L'energie Atomique Et Aux Energies Alternatives

Peptide having anticancer activity, and pharmaceutical composition and dietary supplement composition for preventing and treating cancer, both of which contain same as active ingredient

The present invention relates to a peptide having an anticancer activity, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient and, more specifically, to a peptide binding to transcription factor cp2c, having an activity of preventing and treating cancer and represented by seq id no: 1, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient. <seq id no: 1> asn-tyr-pro-gln-arg-pro when cancer cells are treated with the peptide and the pharmaceutical composition containing the same, according to the present invention, the peptide can specifically bind to cp2c by passing, with very high stability, through the cell membrane and can inhibit the dna binding ability of cp2c, thereby disturbing cp2c-mediated cancer cell-specific transcriptional activity through the inhibition of cp2c activity, and thus the present invention can be effectively used for specifically treating only cancer cells, and can be utilized for cancer prevention and as a dietary supplement additive therefor..
Iucf-hyu (industry-university Cooperation Foundation Hanyang Univerity)

Substituted pyrrolo[2,3-d]pyrimidines

This invention relates to compounds that inhibit e1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia..
Millennium Pharmaceuticals, Inc.

Diarylhydantoin compounds

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.. .
The Regents Of The University Of California

Runx2 transcription factor inhibitors and uses thereof

Substituents r1 and r2 independently are h, cl, f, br, ch3, cf3, sh, —n(c1-3alkyl)2, —nhc(o)c1-3alkyl, or —nhc(o)c5-7cycloalkyl, substituent r3 is h or c1-3 alkyl and r4 is a bridged cycloalkene such as a bridged cyclohexene or a bridge-substituted cyclohexene. The compounds are therapeutics to treat a cancer, such as breast cancer, or metastatic cancers, to inhibit runx2 activity, such as protein expression, in a cancer cell and to increase survival of a subject with breast cancer..

Pharmaceutical composition for treating and/or preventing cancer

An object of the present invention is to identify a cancer antigen protein specifically expressed on the surface of cancer cells and provide use of an antibody targeting the cancer antigen protein as a therapeutic and/or prophylactic agent for cancer. A pharmaceutical composition for treating and/or preventing cancer comprising an antibody or a fragment thereof having immunological reactivity with cspg5 protein consisting of any one of amino acid sequences represented by seq id nos: 8, 4, 6, 10, and 12 and an amino acid sequence having an amino acid identity of 80% or more to the amino acid sequence, or a fragment thereof consisting of 7 or more consecutive amino acids, as an active ingredient..
Toray Industries, Inc.

Dna vector and transformed tumor cell vaccines

Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with s.
Morphogenesis, Inc.

Compositions for overcoming anti-cancer drug-resistance or compositions for anti-cancer activity employing cage-derived peptides

A pharmaceutical anticancer or anticancer drug-resistance composition for a cancer cell, containing a cage-derived peptide, is provided. The pharmaceutical anticancer composition contains an effective ingredient of the cage-derived oligopeptide with seq id no.1 or seq id no.2 and reduces anticancer drug resistance or exhibits an anticancer effect.
L-base Co., Ltd.

Universal immune cells for cancer immunotherapy

Embodiments of the disclosure encompass adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (cars). In specific embodiments, t cells express a her2-specific car, an il13 rα2-specific car, and an epha2-specific car.
Baylor College Of Medicine

Local application of d-lactic acid dimer is selectively cytotoxic when applied to cancer cells

At equimolar concentrations, d-lactic acid dimer is more cytotoxic than l-lactic acid when directly applied to human hela cells in culture. The cytotoxicity of d-lactic acid dimer is an independent effect exclusive of the lower ph when applied to cancer cells in culture.

Salts of quinazoline derivative and preparing the same

The present application relates to maleates of a compound of formula i, methods for preparing the same, pharmaceutical compositions thereof and uses thereof in the treatment of tumors, such as non-small cell lung cancer, breast cancer, and other malignant tumors.. .
Lianyungang Runzhong Pharmaceutical Co., Ltd.

Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a vda and topoisomerase inhibitor

The present invention relates to a pharmaceutical combined composition for preventing or treating cancer comprising a compound of formula 1 or a pharmaceutically acceptable salt thereof and topoisomerase inhibitor as active ingredients. The pharmaceutical combined composition of the present invention specifically inhibits cell proliferation and induces apoptosis as to various cancers such as colorectal cancer and ovarian cancer that a vascular disrupting agent cannot treat due to a complex inhibition mechanism of neoplasm of the compound of formula 1 and the pharmaceutically acceptable salt thereof and topoisomerase inhibitor, and thereby it can be usefully used for preventing and treating cancer..
National Cancer Center

Methods for treating cancer with rorgamma inhibitors

The present invention provides compositions, methods, and kits comprising one or more rorγ inhibitors, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (crpc), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma, and glioma.. .
The Regents Of The University Of California

Method of use of diterpenoid derivatives as anticancer agents

The present invention relates to a group of derivatives synthesized based on the ent-kaurane diterpenoid flexicaulin a and the methods to synthesize such diterpenoid derivatives. In particular, the chemical entities of such synthetic diterpene compounds in the manufacture of a medicament is for the treatment of tumors or cancers..
Hong Kong Baptist University

Sab as a biomarker for degenerative diseases and therapeutic sensitivity in cancers

The current invention pertains to a method of diagnosing a disease or identifying an increased likelihood of developing the disease in a subject. The method comprises determining the level of src homology 3 domain binding protein 5 (sh3bp5 or sab) or the rna encoding sab protein in a biological sample obtained from the subject and identifying the subject as having the disease or having an increased likelihood of developing the disease if the biological sample obtained from the subject has an altered level of sab protein or the rna encoding sab protein relative to a control sample.
The Florida International University Board Of Trustees

Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling

The present invention provides methods for selecting a suitable anticancer drug therapy, and for identifying and predicting response, for the treatment of colorectal cancer. The present invention also provides methods for monitoring the status of colorectal cancer and monitoring how a patient with colorectal cancer is responding to anticancer drug therapy.
Pierian Holdings, Inc.

Methods for breast cancer risk assessment

The present invention relates to methods and systems for assessing the overall risk of a human female subject for developing a breast cancer phenotype. In particular, the present invention relates to combining clinical risk assessment and genetic risk assessment to improve risk analysis..
Genetic Technologies Limited

Marker genes for prostate cancer classification

The present invention relates to a method for classifying a prostate cancer in a subject, the method comprising the steps of a) determining a gene expression level or gene expression pattern of the genes f3 and igfbp3 in a sample from the subject and b) classifying the tumor by comparing the gene expression level determined in a) with a reference gene expression of the same genes in reference patients known to have a high risk or low risk tumor respectively. In addition the invention relates to a method for determining prognosis of a subject diagnosed with prostate cancer, a method for making a treatment decision for a subject diagnosed with prostate cancer and a solid support or a kit for classifying a tumor in a subject diagnosed with prostate cancer..
Chundsell Medicals Ab

Methods and materials for assessing and treating cancer

This document provides methods and materials involved in assessing cancer (e.g., breast cancer). For example, methods and materials for determining whether or not a cancer patient (e.g., a breast cancer patient) having er−/pgr−/her2− cancer cells is likely to have a favorable or unfavorable outcome and/or is likely to respond a cancer treatment that includes a pd-1 inhibitor and/or pd-l1 inhibitor in combination with a jak2 inhibitor are provided.
Mayo Foundation For Medical Education And Research

Compositions and methods for the detection and treatment of cervical cancer and cervical intraepithelial neoplasia

Described herein are biomarkers for hpv-associated pre-cancers and cancers such as cervical cancer and cervical intraepithelial neoplasia. The rna binding protein (rbp) and long-noncoding rna (lnc-rna) biomarkers can be detected and used to diagnose hpv-associated pre-cancers and cancers.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Methods of using pvt1 exon 9 to diagnose and treat prostate cancer

Pvt1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer.
Research Foundation Of The City University Of New York

Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors

The present invention concerns methods and compositions comprising an anti-igf-1r antibody or fragment thereof for treatment of cancer or autoimmune disease. Preferably, the cancer is renal cell carcinoma, breast cancer or pancreatic cancer.
Ibc Pharmaceuticals, Inc.

Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer

A method for treating lung cancer (e.g., non-small cell lung cancer) with an anti-pd-l1 antibody (medi4736), alone or in combination with an anti-ctla4 antibody (tremelimumab), in a patient identified using a polynucleotide marker of ifngamma.. .
Medimmune Limited

Humanized antibodies to liv-1 and use of same to treat cancer

The invention provides humanized antibodies that specifically bind to liv-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting liv-1..
Seattle Genetics, Inc.

Peptide having eight amino acid sequences derived from cage and retaining anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug-resistant cancer cells

The present invention relates to a peptide having eight amino acid sequences derived from cage and retaining anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells and, specifically, to a peptide, which has an amino acid sequence of seq id no: 1 (aqtgtgkt) and thus binds to the cage protein, thereby inhibiting an inter-linkage between cage and gsk3β, thus exhibiting anticancer activity and activity to promote anticancer drug sensitivity of anticancer drug resistant cancer cells, and to a pharmaceutical composition, containing the peptide, for anticancer use or anticancer drug aiding.. .
L-base Co., Ltd.

Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof

The present invention relates to a novel compound of 4′-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same and an application thereof. Specifically, the present invention relates to a phosphamide derivative of 4′-thionucleoside, a preparation method therefor, a pharmaceutical composition comprising the same, a use thereof in the preparation of a medicine for preventing or treating abnormal cell proliferation diseases (for example, tumors or cancers and related diseases) or virus infectious diseases, and a method of using the same for preventing or treating abnormal cell proliferation diseases (for example, tumors or cancers and related diseases) or virus infectious diseases..
Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

Pyrazolone compounds and uses thereof

The invention disclosed herein is directed to compounds of formula i [formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of formula i, or a pharmaceutically acceptable salt thereof.
Tempest Therapeutics, Inc.

Glaucocalyxin a derivative and preparation method and application thereof

Provided is a glaucocalyxin a derivative, or salt thereof, as represented by the formula (i), a method for preparation of said glaucocalyxin a derivative, and a use for said glaucocalyxin a derivative in preparing pharmaceuticals for fighting autoimmune diseases and tumors, e.g. Difficult-to-treat diseases such as systemic lupus erythematosus, psoriasis and triple-negative breast cancer.
Suzhou Pharmavan Cancer Research Center Co., Ltd.

Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens

The present disclosure relates to conjugates, preferably, antibody-drug conjugates, directed against select non-transmembrane tumor antigens that are normally intracellular but can be secreted from cancer cells, such as human cathepsin d, and can be targeted in a way that enables the selective delivery of the conjugate to cancer cells. The design and mechanism of action disclosed enable the preferential delivery of the conjugate prodrug to cancer cells over normal cells for the purpose of selectively killing cancer cells.
Immunobiochem Corporation

Cd38 ligand-drug conjugates for targeted cancer therapy

Disclosed are compositions and methods relating to nucleic acid aptamers that specifically target cd38 protein and also selective binding to cd38-expressing cells. The ligand-drug conjugates specifically target cd38-expressing cancer cells and subsequently internalize into the cell..
The Methodist Hospital System

Method for treating infectious diseases using emissive energy

The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation.
Marv Enterprises, Llc

Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Described herein are methods for the treatment of cancer in a subject. In particular, methods are provided for the treatment of non small cell lung cancer and melanoma with a combination of entinostat and an anti-pd-1 or an anti-pd-l1 antibody..
Syndax Pharmaceuticals, Inc.

Combination immunotherapy for small cell lung cancer

A method is disclosed for treating small cell lung cancer (sclc) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (atra).
H. Lee Moffitt Cancer Center And Research Institute, Inc.

Compositions and methods of treating renal cell cancer

The present invention provides compositions and methods for treating renal cell carcinoma. .
Beth Israel Deaconess Medical Center

Methods of cancer treatment using activated t cells

Provided is a method of treating a cancer in an individual using activated t cells or pbmcs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual.
Syz Cell Therapy Co.

Macrophage activating factor for treating benign or precancerous papillomas

Provided are pharmaceutical compositions including macrophage activating factor derived from gc protein (gcmaf) for use in treating benign or precancerous papillomas. Further provided are pharmaceutical compositions including gcmaf for use in treating recurrent respiratory papillomatosis (rrp)..
Efranat Ltd.

Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists, and immunotoxins

This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. Tnfr25 agonists disclosed herein have an anti-inflammatory and healing effect.
University Of Miami

Methods and materials for treating cancer

This document provides methods and materials for treating cancer. For example, this document provides methods for using compositions containing a potato polysaccharide preparation to reduce the number of cancer cells in a mammal.
The Research Foundation For The State University Of New York

Compositions and methods for preventing colorectal cancer

Provided herein are compositions and methods for preventing and/or reducing the risk of colorectal cancer. In particular, provided herein are probiotic and small molecule agents and their use in preventing colorectal cancer..
Trustees Of Tufts College

Micronutrient formulations for environmental exposure applications

A radioactive protection micronutrient formulation system is provided and the system comprises: a formulation consisting essentially of antioxidants, the antioxidants are selected from the group consisting essentially of vitamin c, vitamin e, n-acetyl cysteine, natural mixed carotenoids, and alpha-lipoic acid, vitamin a (palmitate), vitamin d-3 (cholecalciferol), thiamine mononitrate, riboflavin, niacinamide ascorbate, d-calcium pantothenate, pyridoxine hydrochloride, cyanocobalamin, folic acid, d-biotin, selenium (1-seleno-methionine), chromium picolinate, zinc glycinate, calcium citrate and magnesium citrate and mixtures thereof; and plus a booster formulation selected from a group consisting essentially of vitamin c, d-alpha tocopheryl acid succinate, alpha tocopherol, n-acetyl cysteine, natural mixed carotenoids and alpha lipoic acid, the formulation is designed to reduce the risk in humans exposed to doses of ionizing radiation of becoming subjected to at least one condition selected from the group consisting essentially of radiation-induced acute leukemia, breast cancer, thyroid cancer and other somatic and heritable mutations.. .

Kits for indentifying and treating subjects resistant to acetyl salicylic acid

In alternative embodiments, the invention provides compositions and methods for overcoming or diminishing or preventing growth factor inhibitor resistance in a cell, or, a method for increasing the growth-inhibiting effectiveness of a growth factor inhibitor on a cell, or, a method for re-sensitizing a cell to a growth factor inhibitor, comprising for example, administration of a combination of a tbk1 inhibitor and an rtk inhibitor. In alternative embodiments, the cell is a tumor cell, a cancer cell or a dysfunctional cell.

Novel therapies for cancer

The invention relates to 6-{4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-n-(pyridin-4-yl)pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof, for use in treatment of cns cancers. The invention also relates to combination treatments with irradiation and/or a chemotherapeutic agent for use in the treatment of cancer.
Proximagen Limited

Medical methods utilising high purity diaminophenothiazinium compounds

This disclosure pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including methythioninium chloride (mtc) (also known as methylene blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (nos); nitrosyl reduction (nr); thiosulfonic acid formation (tsaf); oxidative coupling (oc); cr(vi) reduction (cr); isolation and purification of zwitterionic intermediate (iapozi); ring closure (rc); chloride salt-formation (csf); one of: sulphide treatment (st); dimethyldithiocarbamate treatment (dt); carbonate treatment (ct); ethylenediaminetetraacetic acid treatment (edtat); organic extraction (oe); and recrystallisation (rx).
Wista Laboratories Ltd.

Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

Combination therapy regimens including liposomal irinotecan, oxaliplatin and 5-fluorouracil are useful in the treatment of pancreatic cancer, including treatment of patients diagnosed with previously untreated metastatic adenocarcinoma of the pancreas. The combination therapy can include the administration of liposomal irinotecan, oxaliplatin, leucovorin and 5-fluorouracil once every two weeks..
Ipsen Biopharm Ltd.

Methods for treating cancer with trka receptor tyrosine kinase antagonists

The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.. .

Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers..
Ions Pharmaceutical S.à R.l.

Methods and use of compounds that bind to rela of nf-kb

The invention provides methods and agents that modulate rela activity. These methods and modulators of rela activity can be used to treat cancer progression of basal-like breast cancer, such as triple-negative breast cancer..
Cedars-sinai Medical Center

Predictive biomarkers for ovarian cancer

Methods are provided for predicting the presence, subtype and stage of ovarian cancer, as well as for assessing the therapeutic efficacy of a cancer treatment and determining whether a subject potentially is developing cancer. Associated test kits, computer and analytical systems as well as software and diagnostic models are also provided..
Vermillion, Inc.

Methods and compositions for personalized medicine by point-of-care devices for fsh, lh, hcg and bnp

The present invention relates to biomarkers, methods, devices, reagent, systems and kits for the detection, diagnosis of ovarian cancer as well as for the monitoring of ovarian cancer progression and for monitoring the progress of various cancer treatmeats including ovarian cancer. The present invention also relates to point-of-care testing (poct) and methods for determining concentrations of biomarkers in a subject..
Autotelic Llc

Lung cancer biomarkers

The present invention relates to methods of diagnosing lung cancer in a patient, as well as methods of monitoring the progression of lung cancer and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein..
Meso Scale Technologies, Llc.

Biomarkers for diagnosis and prognosis of lung cancer

Provided herein are methods for non-invasively diagnosing and/or prognosing a lung cancer and for determining the efficacy of a therapeutic treatment regimen for the lung cancer. Expression levels of at least two small non-coding rnas, for example, micrornas and small nucleolar rnas, are measured and used to calculate an area under the curve (auc) that provides a probability of lung cancer in the subject.
The United States Of America As Represented By The Department Of Veterans Affairs

System and high throughput screening of cancer cells

The present invention discloses a method for high throughput screening (hts) for identifying an analyte with a measurable effect on cells. The aforementioned method comprises steps of: (a) providing an array comprising a plurality of cell samples; (b) providing at least one analyte to be tested; (c) contacting said cell samples with said analyte; and (d) detecting a signal indicative of said measurable effect on cells, wherein alteration of said signal over time measured on said cell sample relative to a control sample, is indicative of said measurable effect of said analyte on said cell sample.
Cannabics Pharmaceuticals Inc

Method for predicting responsiveness to phosphatidylserine synthase 1 inhibitor

It is intended to develop a therapeutic strategy for specifically targeting cancer cells having the functional suppression of pss2. The present inventors have found that pss1 and pss2 are in a synthetic lethal relationship, and treatment inhibiting pss1 serves as a promising approach for the treatment of cancer having the functional suppression of pss2.
Daiichi Sankyo Company, Limited

Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis

The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer.
Tron - Translationale Onkologie An Der Universitatsmedizin Der Johannes Gutenberg

Furin-knockdown and gm-csf-augmented (fang) cancer vaccine

Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for furin knockdown and gm-csf expression.
Gradalis, Inc.

Anti-cspg4 reagents and methods of treating cancer

Embodiments of the present invention provide antibodies, antigen binding portions thereof, and other polypeptides (e.g., cars), that specifically bind to cspg4, an antigen expressed on cancer cells. Monoclonal antibodies, antibody-drug conjugates, and/or car-t-cells that specifically bind to cspg4 positive cancer cells are also provided..
The General Hospital Corporation

Cancer stem cell targeting peptide and use thereof

A synthetic peptide that targets cancer stem cells is provided. The peptide consists of the amino acid sequence of anyone of seq id no: 1 to seq id no: 15.
Agricultural Technology Research Institute

Novel aspirin derivatives and uses thereof

The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer..
North Carolina Agricultural And Technical State University

Polypeptide that binds aberrant cells and induces apoptosis

Described are proteinaceous molecules comprising at least a domain that comprises an amino acid sequence that specifically binds to an mhc-peptide complex on an aberrant cell, functionally connected with a substance that induces apoptosis in aberrant cells, but not in normal cells. These proteinaceous molecules are preferably used in selectively modulating biological processes.
Apo-t B.v.

Methods for the effective treatment of metastatic cancer

The present invention relates to methods for the treatment of metastatic cancer. Methods of treating metastatic cancer by administration of a set of drugs overcome multiple mechanisms of melphalan resistance and hypersensitize cancer cells to melphalan are described.
General Oncology, Inc.

Glucocorticoid receptor modulators to treat pancreatic cancer

The nonsteroidal sgrm may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a grm are disclosed.

Methods for the treatment of bladder cancer

The present disclosure related to a method of treating bladder cancer in a subject in need of treatment, by administering to the subject an amount of a prodrug of mitomycin c that yields a therapeutically effective amount of mitomycin c. In one embodiment, the prodrug of mitomycin c is a liposomal-prodrug of mitomycin c.
Lipomedix Pharmaceuticals Ltd.

Differential atlas for cancer assessment

Methods and apparatus associated with producing a quantification of differences associated with biochemical recurrence (bcr) in a region of tissue demonstrating prostate cancer (pca) are described. One example apparatus includes a set of logics, and a data store that stores a set of magnetic resonance (mr) images acquired from a population of subjects.
Case Western Reserve University

Compositions, methods and kits for diagnosis of lung cancer

Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions.
Integrated Diagnostics, Inc.

Method for using information on complex biomarker group to diagnose lung cancer in a subject and diagnostic kit and computing system using the same

A method for diagnosing lung cancer in a subject by using a complex biomarker group is provided. The method includes steps of: (a) a computing system (1) acquiring a model m by using expression level data by individual biomarkers in the complex biomarker group and then (2) acquiring expression level data by the individual biomarkers measured from a biological specimen of the subject or their processed data bk; and (b) the computing system determining whether lung cancer is detected in the subject by using the acquired data of the subject by referring to the model m; wherein the complex biomarker group includes cea, he4, apoa2, ttr, svcam-1 and rantes..
Bioinfra Inc.

Biomarkers for the early detection of breast cancer

The present invention provides reagents and methods for breast cancer detection.. .
Dana-farber Cancer Institute, Inc.

Molecular markers and methods for sample analysis via mass spectrometry

Methods for detecting cancer cells, or aggressive cancers, by measuring levels of cardiolipin molecules are provided. Methods of treating identified cancers are likewise provided.
Board Of Regents, The University Of Texas System

Method for detecting lung cancer using lung cancer-specific methylation marker gene

The present invention relates to a method for detecting lung cancer using a lung cancer-specific biomarker, and more particularly to a biomarker for lung cancer diagnosis, which can detect methylation of pcdhga12 gene whose 5′utr or exon 1 region is specifically methylated in lung cancer cells, and to a method of detecting lung cancer and the stage of its progression using the biomarker. The diagnostic kit according to the present invention makes it possible to diagnose lung cancer at an early stage in an accurate and rapid manner compared to conventional methods and can be used for prognosis and monitoring of lung cancer and the stage of its progression..
Genomictree, Inc.

Biomarkers in cancer, methods, and systems related thereto

This disclosure relates biomarkers of cancer, e.g. Prostate cancer.
Emory University

Gene expression panel for breast cancer prognosis

The invention described in the application relates to a panel of gene expression markers for node-negative, er-positive, her2-negative breast cancer patients. The invention thus provides methods and compositions, e.g., kits and/or microarrays, for evaluating gene expression levels of the markers and methods of using such gene expression levels to evaluate the likelihood of relapse of a node-negative, er-positive, her2-negative breast cancer patient.
Oregon Health And Science University

Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease

Provided are methods and compositions for identifying a mirna profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient.. .
Interpace Diagnostics, Llc

Replication factor c-40 (rfc40/rfc2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer

The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (tnbc), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor c 40 (rfc40). Methods and assays for evaluating breast cancer are provided.
Raadysan Biotech, Inc.

Cancer cell enrichment system

Embodiments of the invention relate to a cell culture incubator having a gas flow regulation system that exerts control over atmospheric parameters within the incubator. Particular embodiments include an enclosed environmental chamber and a control unit operably linked thereto, the control unit having an oxygen module and a pressure module.
Xcell Biosciences, Inc.

Biotherapeutics targeting gpr158 for cancer

Prostate cancer (pca) is typically associated with genetic alterations involving androgen sensitivity and the androgen receptor (ar). Described herein is the expression, molecular regulation, subcellular localization and functional role of a g-protein coupled receptor, gpr158, wherein different four human pca cell lines with variable alterations in the ar result in various degrees of androgen-responsiveness, androgen-sensitivity and ar expression.
University Of Southern California

Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ror1 antibodies or antigen binding fragments, ror1 binding peptides and ror1 vaccines.. .
The Regents Of The University Of California

Anti-icos antibodies

Antibodies that bind icos (inducible t cell co-stimulator). Therapeutic use of anti-icos antibodies for modulating the ratio between regulatory t cells and effector t cells, to stimulate the immune system of patients, including use in treating cancers.
Kymab Limited

Targeted/immunomodulatory fusion proteins and methods for making same

The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells.. .
Biocon Limited

Antagonists of il-17 isoforms and their uses

The invention relates generally to antagonists of il-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.. .
Orega Beach

I domain chimeric antigen receptor specific to icam-1

The present invention relates to chimeric antigen receptors (cars) specific to icam-1 comprising i domain of the αl subunit of human lymphocyte function-associated antigen 1 (lfa-1). The invention particularly relates to cars comprising human i domains having different affinities (1 mm to 1 nm kd) to icam-1.
Cornell University

Targeting trastuzumab-resistant her2+ breast cancer with a her3-targeting nanoparticle

Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-her2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-her2 therapy resistant her2+ breast cancer cell, the method comprising contacting the anti-her2 therapy resistant her2+ breast cancer cell with the drug delivery molecule.
Cedars-sinai Medical Center

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Class i mhc phosphopeptides for cancer immunotherapy and diagnosis

A set of phosphorylated peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive t-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease.
Agenus Inc.

Method for preparing site-specifically modified protein based on novel carbon-carbon bond formation

A method for producing a site-specifically modified protein based on new carbon-carbon bond formation is disclosed, including the following three steps (marking, activation, and coupling steps): (a) marking of the modification site by incorporating a specific amino acid into a selected position of a target protein; (b) activation of the marked site; and (c) coupling of various post-translational modification (ptm) moieties or other chemical groups onto the activated site to obtain a site-specifically modified protein. The method for producing a site-specifically modified protein can incorporate desired diverse chemical groups including post-translational modification (ptm) moieties into a designated site in a target protein through a new carbon-carbon bond.
Korea Advanced Institute Of Science And Technology

E-selectin antagonist compounds, compositions, and methods of use

Methods and compositions using e-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of e-selectin to an e-selectin ligand. Described herein are e-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation..
Glycomimetics, Inc.

Site specific curcumin-polymer molecular complexes and methods of treating colon diseases and inflammation

Methods and materials relating to a medicament preparation comprising a curcuminoid component, such as curcumin, and a polymer component having a backbone comprising polymethacrylate or methyl methacrylate provided as a curcuminoid-polymer complex, which enhances the solubility, stability and bioavailability of the curcumin component and are useful for the treatment of various inflammatory diseases and conditions when delivered to the gastro-intestinal tract, including sepsis, mucositis, gastritis, infections, inflammatory bowel disease and cancers of git. The curcumin-polymer complex inhibiting the activation of tlr receptors and thereby reduce the release of inflammatory cytokines, such that the curcumin-polymer complexes are more potent than free curcumin in antagonizing on the activation of tlr4..
South Dakota Board Of Regents

Anti-dc-hil antibodies for cancer diagnosis, prognosis and therapy

The present disclosure is directed to antibodies that bind to dc-hil on the surface of myeloid-derived suppressor cells, and thus antagonize the t cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.. .
The Board Of Regents Of The University Of Texas System

Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide

This document provides methods and materials for generating cd8− t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide. For example, methods and materials for using a polypeptide consisting of an slaflpesfd amino acid sequence in vivo or in vitro to generate cd8+ t cells having the ability to recognize and lyse cancer cells expressing a her2/neu polypeptide are provided..
Mayo Foundation For Medical Education And Research

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel msln targeting dna vaccine for cancer immunotherapy

The present invention relates to an attenuated mutant strain of salmonella comprising a recombinant dna molecule encoding mesothelin. In particular, the present invention relates to the use of said attenuated mutant strain of salmonella in cancer immunotherapy..
Vaximm Gmbh

Methods and pharmaceutical compositions for the treatment of pancreatic cancer

The present invention relates to methods and pharmaceutical compositions for the treatment of pancreatic cancers. In particular, the present invention relates to an ox1r agonist for use in the treatment of pancreatic cancer in a subject in need thereof..
Universite De Versailles Saint-quentin-en-yvelines

Pet imaging tracer for imaging prostate cancer

In various embodiments, the invention provides a radiotracer comprising a positron emitting atom bound to a deoxy sugar moiety. The radiotracer is reversible bound to a caging moiety that prevents or retards tissue uptake of the radiotracer while the caging moiety is in place.
The Regents Of The University Of California

Compositions and methods for treatment of prostate cancer

The present invention relates to compositions and methods for the treatment of prostate cancer. The present invention relates to polyamides and prostate agents, for example, to inhibit an androgen receptor signaling axis, and the use of these compositions in the treatment of prostate cancer..
California Institute Of Technology

Use of cabazitaxel in the treatment of prostate cancer

The present invention relates to cabazitaxel for use in a method for treating an ar-v7-positive patient suffering from prostate cancer comprising determining the ar-v7-status in said patient and administering cabazitaxel. The invention also relates to a method of identifying patients with prostate cancer, eligible for treatment with cabazitaxel comprising testing a biological sample from the patient for the presence of ar-v7 circulating tumor cells, wherein the patient is eligible for treatment with said cabazitaxel if circulating tumor cells in said sample test positive for ar-v7.
Erasmus University Medical Center Rotterdam

Methods of treating or preventing prostate cancer

In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.. .
Amarin Pharmaceuticals Ireland Limited

Novel compositions and uses of metformin agents

Methods and compositions for improving the delivery and/or efficacy of a therapy (e.g., an anti-cancer, anti-fibrotic or anti-inflammatory therapy) are disclosed. The invention is based, at least in part, on the discovery that metformin, a widely prescribed anti-diabetic drug, can affect the tumor microenvironment (e.g., directly, i.e., independent of its effects on cancer cells themselves or tumor metabolism).
Xtuit Pharmaceuticals, Inc.

Bisphenol ether derivatives and methods for using the same

Compounds having a structure of formula i, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein r1, r2, l1, l2, l3, x, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided..
British Columbia Cancer Agency Branch

Transgenic mouse capable of spatial and temporal control of expression and site-specific modification of target protein, production method and uses thereof

The present invention relates to a mouse (mus musculus) in which expression and site-specific modification of a target protein is temporally and spatially controlled, and a method for producing the same and the use thereof, and more particularly to a transgenic mouse in which expression of a target protein having a modification attached to a specific position is temporally and spatially controlled as a result of incorporation of an unnatural amino acid. In the mouse according to the present invention, in which site-specific modification of a target protein is temporally and spatially controllable, expression of the target protein having the site-specific modification attached thereto is controllable depending on the timing and/or position of introduction of an unnatural amino acid.
Korea Advanced Institute Of Science And Technology





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cancer for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cancer with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.9695

file did exist - 12474

1 - 1 - 253